Important determinants of bone strength - Beyond bone mineral density

被引:108
作者
Friedman, AW [1 ]
机构
[1] Med Clin Houston, Houston, TX 77005 USA
关键词
osteoporosis; bone turnover; microarchitecture; bone mineral density;
D O I
10.1097/01.rhu.0000208612.33819.8c
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength that predisposes individuals to increased fracture risk. Bone strength is determined by its material and structural properties. Bone mineral density (BMD) is a useful tool for diagnosis; however, this parameter provides information regarding only the quantity of mineral in bone, which is only one component of bone strength. Osteoporosis treatments have been shown to have beneficial effects on bone turnover, microarchitecture, and/or mineralization, all of which can help account for the reductions in fracture risk above and beyond changes in BMD. Newer noninvasive imaging methods are being developed that assess bone strength independent of BMD, and these methods should improve the assessment of fracture risk and response to treatment. These imaging methods are not currently available for routine clinical use, and therefore, clinicians need to continue for now to rely on surrogate markers of bone fragility, including BMD, prevalent fracture, and other important risk factors for fracture.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 108 条
[1]
Bone loss in relation to menopause: A prospective study during 16 years [J].
Ahlborg, HG ;
Johnell, O ;
Nilsson, BE ;
Jeppsson, S ;
Rannevik, G ;
Karlsson, MK .
BONE, 2001, 28 (03) :327-331
[2]
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study [J].
Albrand, G ;
Munoz, F ;
Sornay-Rendu, E ;
DuBoeuf, F ;
Delmas, PD .
BONE, 2003, 32 (01) :78-85
[3]
Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats [J].
Ammann, P ;
Rizzoli, R ;
Meyer, JM ;
Bonjour, JP .
OSTEOPOROSIS INTERNATIONAL, 1996, 6 (03) :219-227
[4]
[Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
[5]
[Anonymous], 1996, Arthritis Rheum, V39, P1791
[6]
[Anonymous], 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X
[8]
BELL G. H., 1967, CALCIFIED TISSUE RES, V1, P75, DOI 10.1007/BF02008077
[9]
Black DM, 1999, J BONE MINER RES, V14, pS158
[10]
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541